Search bioRxiv⌕ Search

Biology subjects

Tripathi, S.

Publications and source records attributed to Tripathi, S..

At least 19 recordsLinked to original sources

Tracking gene flow in the gut microbiome reveals phage activation and host-range expansion in response to diet

Horizontal gene transfer (HGT) drives microbial evolution, but what determines when genes move between species within complex communities remains unclear. We developed a junction-resolved metagenomic framework using short-read sequencing to distinguish mobile genetic element activation from de novo transfer and track both longitudinally. In a defined human gut community colonizing mice, mobile element activation was widespread but successful transfer was rare. A prophage carried by invading Phocaeicola vulgatus transferred reproducibly to resident species when the community resisted invasion, but not when dietary perturbation allowed the invader to expand. Transfer required prophage activation and persistence of a permissive recipient and coincided with diversification of a phage receptor-binding protein. Dietary polysaccharides reproduced prophage-associated fitness costs in vitro, and rhamnogalacturonan I induced cell lysis consistent with productive prophage activation. The framework also detected interspecies transfer retrospectively in longitudinal human metagenomes. Thus, diet and community ecology can redirect gene flow through the gut microbiome.

microbiology↗

Myeloid-targeted RNA nanotherapeutics rewire cholesterol metabolism to unleash anti-tumor immunity in glioblastoma

Tumor-associated myeloid cells (TAMCs) dominate the glioblastoma (GBM) microenvironment and suppress anti-tumor immunity. Here, we identify cholesterol efflux via ABCA1 as a targetable metabolic checkpoint controlling TAMC immunosuppression in GBM. Reprogramming TAMC cholesterol metabolism using TAMC-targeting lipid nanoparticle encapsulating ABCA1 siRNA (ABCA1 LNP) converts TAMCs into potent antigen-presenting cells with enhanced pro-inflammatory activity and antigen-presenting capacity, thereby inducing T cell activation, expansion, and tumor infiltration. Mechanistically, ABCA1 blockade induces cholesterol accumulation in TAMC membranes, promoting lipid raft formation and enhancing MHC-I-mediated antigen presentation. In multiple preclinical GBM models, ABCA1 LNP treatment dramatically induces T cell priming, extends animal survival, and overcomes GBM resistance to radiotherapy and immune checkpoint therapy. This efficacy was well-maintained in stem-like and recurrent GBM models, GBM patient specimens, and a renal cell carcinoma model. Altogether, our work identifies cholesterol efflux as a targetable metabolic vulnerability in TAMCs to overcome therapy resistance in myeloid-rich, immunologically "cold" tumors.

immunology↗

HIV-1 Hijacks HGF/c-MET Signaling to Promote Viral Entry and Replication in Primary CD4⁺ T Cells

The mesenchymal-epithelial transition factor (c-MET) is a receptor tyrosine kinase best known for mediating hepatocyte growth factor (HGF) signaling in cancer, yet its role in HIV-1 infection remains undefined. Here we identify c-MET as a host factor that facilitates HIV-1 replication in CD4+ T cells by promoting viral entry. HIV-1 infection upregulates c-MET transcripts and phosphorylation in primary CD4+ T cells. Knockout or pharmacological inhibition of c-MET in CD4+ T cells significantly reduces HIV-1 Gag expression, viral production, and infectivity. Mechanistically, c-MET disruption reduces cell-surface expression of the HIV-1 receptor CD4 and the coreceptor CXCR4, thereby restricting viral entry and infection. Furthermore, c-MET disruption diminishes activation of NF-{kappa}B, STAT1/3, and MAPK signaling pathways that are critical for HIV-1 gene expression. These findings reveal that HIV-1 exploits HGF/c-MET signaling to coordinate entry receptor availability and intracellular signaling, uncovering a previously unrecognized host pathway that supports viral replication in CD4+ T cells. Overall, our results highlight an essential role for HGF/c-MET signaling in HIV-1 infection of primary CD4+ T cells and suggest a potential host-directed therapeutic target. HighlightsO_LIc-MET facilitates HIV-1 replication in CD4+ T cells by promoting viral entry C_LIO_LIHIV-1 infection upregulates c-MET transcripts and phosphorylation in CD4+ T cells C_LIO_LIc-MET disruption reduces CD4 and CXCR4 expression on CD4+ T cell surfaces C_LIO_LIc-MET disruption diminishes activation of cellular pathways important for HIV-1 C_LI

microbiology↗

In-vitro evaluation of Ozenoxacin and other Antibiotics against Staphylococcus aureus and Streptococcus pyogenes isolated from Skin and Soft Tissue Infections

Staphylococcus aureus and Streptococcus pyogenes are major causative bacteria responsible for skin and soft-tissue infections (SSTIs) such as impetigo. Increasing resistance to commonly used topical antibiotics necessitates evaluation of newer agents for the treatment of skin infections. Ozenoxacin, a novel non-fluorinated topical quinolone, has shown promise, exhibiting potent activity against a wide range of pathogens, including methicillin-resistant Staphylococcus (MRSA) and Streptococcus pyogenes. The present study compared the in vitro activity of ozenoxacin and comparator agents against clinical isolates of Staphylococcus aureus and Streptococcus pyogenes from multiple sources including skin and soft-tissue, wound, abscess, and blood. Ozenoxacin was assessed for in vitro antimicrobial activity against 109 methicillin-susceptible (MSSA), methicillin-resistant S. aureus (MRSA), and 24 Streptococcus pyogenes isolates by broth microdilution method recommended by the Clinical and Laboratory Standards Institute (CLSI). Ozenoxacin demonstrated potent in-vitro activity against all 109 S. aureus (MIC50/90= 0.125/0.5 {micro}g/ml) and 24 S. pyogenes (MIC50/90= 0.015/0.03 {micro}g/ml) strains. In contrast, higher MICs were observed for fusidic acid and mupirocin among a subset of S. aureus isolates. A comparison of MIC90values demonstrated that ozenoxacin (0.5 {micro}g/ml) was more active against S. aureus isolates than 8 of the 9 comparator agents tested including vancomycin and linezolid (MIC90= 2 & 4 {micro}g/ml) respectively. In vitro studies of ozenoxacin showed potency against staphylococci and streptococci including resistant S. aureus strains. These findings support its role as an effective first-in-class quinolone topical therapeutic option in the management of various SSTIs.

microbiology↗

Small Molecule Regulation of CLOCK:BMAL1 DNA Binding Activity

CLOCK:BMAL1 is a bHLH-PAS transcription factor complex that utilizes its bHLH (basic helix-loop-helix) domains to bind E-box motifs in DNA and tandem PAS (PER-ARNT-SIM) domains to heterodimerize and interact with regulatory proteins to generate circadian rhythms. PAS domains are evolutionarily conserved modules that frequently bind small molecule ligands within buried cavities to perform sensory and signal transduction functions. CLOCK and BMAL1 PAS domains have cavities that could be leveraged to regulate the transcription factor, and consequently, the circadian clock. Using NMR spectroscopy, we identified small molecules that bind within a cavity inside the PAS-A domain of CLOCK and its paralog NPAS2, which sits at an important flexible junction in the structured core of the heterodimer. We identified a gatekeeping mutant in the core of CLOCK PAS-A that significantly decreased ligand binding affinity. High-pressure NMR studies showed that ligand binding or the gatekeeping mutant significantly stabilized the domain. Finally, we showed that ligands induced dose-dependent displacement of CLOCK:BMAL1 from DNA in vitro. Together, these data demonstrate that small molecules can regulate DNA binding by the circadian transcription factor CLOCK:BMAL1 through occupancy of a PAS domain cavity.

biochemistry↗

Broad protection against Influenza A Viruses via an adjuvant-free mucosal microparticle vaccine with conserved CD8/CD4 bispecific peptides

Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=200 SRC="FIGDIR/small/715080v2_ufig1.gif" ALT="Figure 1"> View larger version (45K): org.highwire.dtl.DTLVardef@19fafedorg.highwire.dtl.DTLVardef@d73109org.highwire.dtl.DTLVardef@1d486edorg.highwire.dtl.DTLVardef@1e663c8_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗

Re-analysis of Transcriptomic and Proteomic Data Using Multi-Omics Approaches Identifies Biomarkers of Diabetes-Associated Complications in an INS Mutant Pig Model

Mutant Insulin Induced Diabetes of Youth (MIDY) is an established porcine model caused by the INSC94Y mutation, which results in misfolded insulin, leading to severe {beta}-cell loss and hyperglycemia. Understanding disease pathophysiology is critical for identifying biomarkers and therapeutic targets, and animal models play a key role in this process. In this study, we re-analyzed published transcriptomic and proteomic data from the MIDY model using advanced multi-omics approaches and our in-house SurfacOmics tool. This integrative analysis identified ADAMTS17 as a novel biomarker, suggesting a potential association in diabetes-associated immune dysfunction and delayed wound healing through ECM-immune interplay.

bioinformatics↗

Cytosolic interaction with RNA-helicase DDX39A titrates viral RNA G-quadruplex mediated α-Synuclein amyloidogenesis

Amyloid aggregates of -Synuclein are hallmark of Parkinsons Disease (PD) and related neurodegenerative diseases. -Synuclein, being an non-canonical RNA-binding protein (RBP), associates with other RBPs within cytosolic RNA-protein granules to modulate mRNA-stability. Conversely, mRNA G-quadruplexes (rG4s) expedite -Synuclein amyloidogenesis. However, spatiotemporal control on -Synuclein amyloidogenesis by other RBPs remains unexplored. Here, we report that RNA-dependent cytosolic interaction with DEAD-box RNA-helicase DDX39A decelerates -Synuclein amyloidogenesis. Viral infections transiently elevate rG4s in cytoplasm. Perturbing interactions between Synuclein and DDX39A using viral rG4s from H1N1-influenza and SARS-CoV-2 genomes expedites intracellular amyloidogenesis. Conversely, DDX39A overexpression alleviates -Synuclein amyloidogenesis in mouse primary neurons triggered by SARS-CoV-2 infection. We demonstrate that while DDX39A unwinds viral rG4s to mitigate -Synuclein sol-gel transition, its reciprocal cooperative phase separation with -Synuclein enhances the helicases rG4-unwinding activity. We propose that accelerated -Synuclein amyloidogenesis represents a trade-off within this RNA-protein interaction equilibrium, contributing to the viral etiology of PD.

biochemistry↗

Prime Editing Models the MTARC1 A165T Variant in Human Liver Organoids, Demonstrating Reduced Steatosis, Inflammation, and Fibrosis

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent cause of chronic liver disease. MASLD is a progressive and multifactorial disease marked initially by hepatic steatosis, which can progress to steatohepatitis, fibrosis, cirrhosis, and liver cancer. Genetic factors influence the development, progression, and complications in MASLD, and genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with altered risk. Mitochondrial amidoxime reducing component 1 (MTARC1) rs2642438 (p.A165T) variant has been identified as protective, but the role of MTARC1 and the impact of this variant in hepatocytes remains poorly understood. Here, we applied prime editing to create the rs2642438 variant in human pluripotent stem cells (hPSCs) before differentiation into human liver organoids (HLOs) to investigate the effect of the variant under conditions of steatotic and fibrotic injury. Compared to HLOs formed from hPSCs containing the MTARC1 reference sequence, HLOs with the rs2642438 variant show lower levels of MTARC1 protein and triglycerides and are protected from steatotic and fibrotic injury, as predicted by the phenotype observed in patients carrying the variant. The observed decrease in triglyceride level with the variant appears to be driven more by suppression of de novo lipogenesis rather than stimulation in {beta}-oxidation in the HLO model. While resmetirom, the thyroid hormone receptor-beta (THRB) agonist approved to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) was effective in reducing triglyceride levels in the setting of steatotic injury in HLOs with the reference sequence, HLOs containing the variant did not show further reduction in triglyceride levels with exposure to resmetirom, despite increased expression of THRB. Together, this study establishes an approach to model disease-related SNPs in HLOs and provides further insights into the activity of the MTARC1 variant, and suggests that profiling SNPs may be a path to identify patients more likely to respond to therapies for MASLD.

cell biology↗

An Oral Combination therapy against SARS-CoV-2 based on Synergistic Action of Auranofin and Remdesivir.

The combination of direct-acting and host-directed antivirals targeting SARS-CoV-2 represents an attractive treatment strategy to combat COVID-19. In our previous work, we showed that the FDA-approved anti-arthritis drug Auranofin restricts SARS-CoV-2 replication and pathology in an animal model. Here, we report that Auranofin inhibits SARS-CoV-2 by targeting viral entry and main protease (Mpro) activity without affecting viral transcription. Time-of-addition studies combined with functional assays of viral entry, protease activity, and cell-cell fusion delineated its inhibitory effects at both early and late stages of the viral life cycle. Molecular docking and isothermal titration calorimetry analyses of Auranofin and the known Mpro inhibitor Nirmatrelvir indicated competitive binding within the Mpro active-site pocket. In addition, Auranofin attenuated NF-{kappa}B-dependent signalling and suppressed proinflammatory cytokine production. Combination studies with SARS-CoV-2 targeting nucleoside analogues, revealed the strongest synergistic antiviral activity with remdesivir in vitro. Comparable synergy was observed between auranofin and GS-621763, the orally bioavailable derivative of remdesivir, and was further validated in a preclinical animal model. Collectively, these findings provide a rationale for the further development of auranofin-nucleoside analog combinations targeting SARS-CoV-2. FundingThis research has been supported by ICMR (IIRPIG-2023-0000978) and BIRAC grant (BT/CS0070/06/22) to ST. We acknowledge the infrastructure and research support provided to IISc by the Crypto Relief Fund, L&T Trust, DST-FIST program, Institute of Eminence Fund, Ministry of Education, and the DBT-IISc partnership program (Phase II). RN acknowledges DBT-RA fellowship, SK acknowledges PMRF fellowship, and RS acknowledges FICCI-PMRF fellowship. Research in contextO_ST_ABSEvidence before this studyC_ST_ABSMultiple previous studies have provided evidence showing that auranofin is an antiviral agent targeting SARS-CoV-2 through a host-targeting mechanism, involving the inhibition of thioredoxin reductase and redox homeostasis. Mixed results have been reported regarding the effect of this drug on inhibiting virus-induced syncytia. A prior study from our lab demonstrated the drugs effectiveness in reducing SARS-CoV-2 viral loads in both cell and animal models. Added value of the studyOur study firmly establishes the synergistic use of Auranofin and Remdesivir GS 621763 in the treatment of SARS-CoV-2 infection.

microbiology↗

Suppressing microtubule detyrosination augments AAV2 endosomal escape and gene delivery.

Adeno-associated virus (AAV) is a widely used vector for gene delivery, yet the host intracellular trafficking barriers often limit its efficacy. Here, we identify microtubule detyrosination--a tubulin post-translational modification--as a key regulator of AAV2 endo-lysosomal processing. Using super-resolution microscopy (SIM/STORM), we show that upon AAV2 endocytosis, the host upregulates microtubule detyrosination via GSK3{beta}-CLASP2 signaling axis. Single particle tracking of the virus reveals that detyrosinated microtubules form a physical and functional barrier, restricting AAV2 motility and promoting lysosomal trapping. Restoring microtubule tyrosination--via tubulin-tyrosine ligase overexpression or pharmacological inhibition of detyrosination with parthenolide--boosted AAV2 endosomal escape, perinuclear accumulation, and gene delivery in cells. Notably, a clinically relevant prodrug of parthenolide, DMAPT, also displayed a similar trend of enhanced AAV2-driven factor IX expression in hemophilia B mouse models. Our findings uncover a host mechanism that reshapes the microtubule landscape to restrict AAV2 trafficking and identify microtubule detyrosination as a novel druggable target to improve AAV2-based gene therapies.

cell biology↗

Differential modulation of Interferon and Cell Death Responses defines Human vs Avian Influenza A Virus Strain-Specific Virulence and guides Combination Therapy.

Influenza A virus (IAV) poses a significant global health risk, with highly pathogenic strains like H5N1 (CFR [~]52%) causing severe disease compared to less lethal but more transmissible strains like H1N1 (CFR 0.01-0.03%). Although IAV primarily infects lung epithelial cells, causing cell death and tissue damage, the molecular basis of strain-specific pathogenesis remains poorly understood. Here we show that in cell culture, H5N1 induced more rapid and extensive cell death than H1N1. Since Interferon (IFN) signaling is key to innate immunity, we examined its role in virus-induced cell death using STAT1-knockout A549 cells and JAK/STAT pathway inhibitors like Baricitinib. Both approaches reduced cell death across various IAV strains, including H1N1, H5N1, H7N9, and H3N2. However, inhibition increased viral titers, raising concerns about its clinical use in isolation. To overcome this, we tested a combination of Oseltamivir (antiviral) and Baricitinib (anti-inflammatory). Post-infection treatment in a murine model reduced lung inflammation and improved survival. Given that both drugs are FDA-approved, this approach has strong translational potential for clinical IAV treatment.

microbiology↗

Constraints and tunability of antigen-agnostic memory durability

Apart from antigen-specific immune memory, infection or vaccination can also induce antigen-agnostic memory including bystander T cell activation memory and trained innate immunity. Determinants of the durability of such memory remain unclear. We developed mathematical models to show that antigen-agnostic memory durability is constrained by immune cell turnover and cytokine dependence. Trained immunity durability is further constrained by the fidelity of epigenetic state transmission during self-renewal and differentiation. Using computer simulations and a machine learning-based parameter-phenotype mapping approach, we find that positive feedback mediated by immune cell-secreted cytokines, a motif seen across immune circuits, can lead to tunable memory involving excitable responses to acute challenges followed by slow relaxation to the pre-challenge baseline. We propose specific experiments to test predictions from our models. Our findings thus reveal a cell extrinsic mechanism that can overcome the constraints imposed by cell turnover and epigenetic state transmission to drive long-lasting, tunable antigen-agnostic memory.

immunology↗

PROFET Predicts Continuous Gene Expression Dynamics from scRNA-seq Data to Elucidate Heterogeneity of Cancer Treatment Responses

Single-cell RNA sequencing profiles cellular heterogeneity but captures only static snapshots, limiting inference of gene expression dynamics. We developed PROFET (Particle-based Reconstruction Of generative Force-matched Expression Trajectories), a framework that reconstructs continuous, nonlinear single-cell trajectories from sparsely sampled scRNA-seq time series. PROFET combines a particle-based gradient-flow algorithm with simulation-free force matching to accurately infer cellular dynamics. Across mouse and human in vitro datasets and an in vivo axolotl regeneration dataset, PROFET achieved 2.6-12.5X lower prediction error than ten state-of-the-art trajectory inference methods. Applying PROFET to newly generated scRNA-seq data from a palbociclib-treated MCF7 cell line and three published breast cancer patient datasets, we reconstructed treatment-response trajectories and identified a resistant cell subpopulation exhibiting large phenotypic shifts and enrichment of the surface markers UNC5B, TLR3, PCDH19, PROCR, SLITRK6, and SEMA6B. PROFET provides a biologically grounded framework for reconstructing cell-state dynamics from static single-cell data across development, regeneration, and therapeutic response.

bioinformatics↗

SurfacOmics: an R shiny application integrating variable Feature Selection for gene biomarker discovery using Elastic-Net Regularization

Affordable sequencing technologies have resulted in a rapid rise in genomic and proteomic data. As a result, a massive amount of data is being analyzed, and the outcomes must be summarized as relevant clinical biomarkers. One of the major challenges is enabling wet-lab researchers to make meaningful inferences from the data, even in the absence of expertise in pipeline development and statistical training. We present a user-friendly R shiny application, SurfacOmics, which allows the user to perform biomarker identification via penalized regression algorithms. It also enables researchers to choose a crucial binary variable, such as treatment or group, from the study design metadata to anticipate potential biomarkers. We have introduced a novel concept of scoring scheme to characterize potential biomarkers for prediction, prioritization, and ranking. The tool integrates Gene Ontology information for sub-cellular localization together with a manually curated knowledgebase to provide valuable insights on biological processes, molecular functions and antibody resources, offering a comprehensive view in a single interface.

bioinformatics↗

Microglial Fructose Metabolism Is Essential for Glioblastoma Growth

Glioblastoma (GBM) is most common and aggressive primary brain tumor in adults, for which standard of care hasnt changed in twenty years. GBM tumor associated macrophages (TAMCs), consisting of infiltrating myeloid cells from the periphery and resident microglia cells, are pro-tumorigenic, promoting tumor growth. Fructose is one of the most abundant metabolites in the GBM tumor microenvironment (TME), as well as in the healthy central nervous system (CNS). In the CNS and GBM, microglia are the predominant expressors of the fructose transporter GLUT5. Mice lacking the GLUT5 transporter (GLUT5-KO) survive significantly longer after orthotopic implantation of two glioma cell lines than wildtype mice, which is not due to dietary fructose or peripherally derived TAMCs. Investigation of the TME showed that GLUT5-KO mice have more highly activated and inflammatory innate and adaptive immune compartments. Microglia cultured in fructose have a decreased phagocytic ability and exhibit decreased inflammatory capacity due to the polyol pathway promoting redox homeostasis.

cancer biology↗

Phospholipid Scramblases TMEM16F and Xkr8 regulate distinct features of Phosphatidylserine (PS) externalization and immune regulation in the tumor microenvironment to regulate tumor growth

The phospholipid scramblases Xkr8 and TMEM16F externalize phosphatidylserine (PS) by distinct mechanisms. Xkr8, is activated by caspase-mediated proteolytic cleavage, and in synergy with inactivation of P4-ATPase flippases, results in the irreversible externalization of PS on apoptotic cells and an "eat-me" signal for efferocytosis. In contrast, TMEM16F is a calcium activated scramblase that reversibly externalizes PS on viable cells via the transient increase in intracellular calcium in live cells. The tumor microenvironment (TME) is abundant with exposed PS, resulting from prolonged oncogenic and metabolic stresses and high apoptotic indexes of tumors. Such chronic PS externalization in the TME has been linked to host immune evasion from interactions of PS with inhibitory PS receptors such as TAM and TIM receptors. Here, in an effort to better understand the contributions of apoptotic vs live cell PS-externalization to tumorigenesis and immune evasion, we employed an E0771 orthotopic breast cancer model and genetically ablated Xkr8 and TMEM16F using CRISPR/Cas9. While neither the knockout of Xkr8 nor TMEM16F showed defects in cell intrinsic properties related to proliferation, tumor-sphere formation, and growth factor signaling, both knockouts suppressed tumorigenicity in immune-competent mice, but not in NOD/SCID or RAG-KO immune-deficient strains. Mechanistically, Xkr8-KO tumors suppressed macrophage-mediated efferocytosis, and TMEM16F-KO suppressed ER stress/calcium-induced PS externalization. Our data support an emerging idea in immune-oncology that constitutive PS externalization, mediated by scramblase dysregulation on tumor cells, supports immune evasion in the tumor microenvironment. This links apoptosis/efferocytosis and oncogenic stress involving calcium dysregulation, contributing to PS-mediated immune escape and cancer progression.

cancer biology↗

Proteome-wide computational analyses reveal links between protein condensate formation and RNA biology

Biomolecular condensates mediate dynamic compartmentalization of cellular processes. The multivalent interactions that underlie biomolecular condensation are often promoted by intrinsically disordered regions (IDRs) within proteins. While the role of IDRs in biomolecular condensates is well appreciated, predicting whether an IDR forms condensates in cells remains challenging. Here, we developed a machine learning model to predict condensation behavior of IDRs, analyzing 215 IDRs from fusion oncoproteins in HEK293T cells. Our study identified distinct sequence-derived physicochemical features associated with condensation. Leveraging these data, our model predicts that [~]12% of the [~]13,000 IDRs in the human proteome are likely to form cellular condensates. Proteins with condensate-forming IDRs are enriched in functions involving RNA-related processes and membrane-less organelles (MLOs), highlighting their role in MLO assembly and function. Our model, available via the SAK3.0 web server (https://sak.stjude.org), provides a powerful resource for studying IDR-driven phase separation across proteomes, offering insights into biomolecular condensates and their biological roles.

bioinformatics↗